R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. [electronic resource]
Producer: 20070515Description: 533-43 p. digitalISSN:- 0021-9541
- Adenocarcinoma -- drug therapy
- Animals
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Apoptosis Regulatory Proteins -- metabolism
- Caspases -- metabolism
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Diphosphonates -- pharmacology
- Dose-Response Relationship, Drug
- Drug Synergism
- Enzyme Activation -- drug effects
- Extracellular Signal-Regulated MAP Kinases -- metabolism
- Humans
- Imidazoles -- pharmacology
- Male
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Phosphorylation -- drug effects
- Prostatic Neoplasms -- drug therapy
- Proto-Oncogene Proteins c-akt -- metabolism
- Proto-Oncogene Proteins c-bcl-2 -- metabolism
- Quinolones -- pharmacology
- Signal Transduction -- drug effects
- Time Factors
- Xenograft Model Antitumor Assays
- Zoledronic Acid
- bcl-Associated Death Protein -- metabolism
- ras Proteins -- metabolism
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.